RedHill Biopharma Ltd (RDHL)

[midastouch017]

Therapy: RIZAPORT (rizatriptan benzoate)

Disease: acute migraine, primarily patients with migraine-related nausea or difficulty in swallowing.

News: RedHill Biopharma is gaining in pre-market trading after announcing resubmission of 505(b)(2) New Drug Application to the FDA seeking approval for RIZAPORT (rizatriptan benzoate) oral thin film formulation for the treatment of acute migraine.

Analysis: RedHill Biopharma is one of the stocks in our conviction buy list, although the stock has had a disappointing performance over the last one year, falling nearly 30%. The refiling, though, could provide a boost to RDHL shares. RIZAPORT is an oral triptan. Globally, sales of other triptans totaled nearly $700 million in 2015, according to EvaluatePharma. Given that RIZAPORT has demonstrated that it is more effective than other triptans, there is potential to win a significant portion of the global market share

https://seekingalpha.com/article/4119519-daily-pharma-scoop-teva-q3-results-boost-redhill-clovis-reports-rubraca-sales?app=1&auth_param=145sp8:1cvm879:1309d4035f5eb1402d1c0f69afca4932&uprof=45&dr=1